Vancomycin Dosing for MRSA Infections
(VIVID Trial)
Trial Summary
What is the purpose of this trial?
This trial tests two ways of giving vancomycin to patients with serious MRSA infections. It aims to find out if a simpler dosing method is as effective as a more complex one. Vancomycin is the antibiotic with the most clinical experience for treating MRSA bacteremia.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that you can participate if you are not currently on vancomycin or have been on it for 4 days or less.
What data supports the effectiveness of the drug Vancomycin for MRSA infections?
Research shows that Vancomycin is effective for treating MRSA infections, especially when the drug concentration in the body is carefully monitored and adjusted. Studies suggest that achieving a specific drug concentration (AUC/MIC ratio of ≥400) is linked to better treatment outcomes, reducing the chance of treatment failure.12345
Is vancomycin generally safe for humans?
How is the drug Vancomycin unique in treating MRSA infections?
Vancomycin is unique in treating MRSA infections because it requires careful dosing to achieve specific drug concentration levels in the body, measured by the area under the concentration versus time curve (AUC) divided by the minimum inhibitory concentration (MIC) of the bacteria. This approach helps ensure the drug is effective, especially in critically ill patients, and differs from traditional dosing methods that focus only on trough concentrations.1381011
Eligibility Criteria
Adults with serious MRSA infections confirmed by culture, including blood, lung, brain, bone infections and more. They must join within 4 days of the culture test and can be new to vancomycin treatment or have had it for up to 4 days. Not eligible if they're on dialysis, expected to die within 48 hours, allergic to vancomycin or if their infection resists higher doses of vancomycin.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intravenous vancomycin with dosing strategy targeting either a trough level of 10 to 15mg/L or an AUC of 400 to 600 for serious MRSA infections
Follow-up
Participants are monitored for treatment failure, defined as death or microbiologic failure, and other secondary outcomes such as nephrotoxicity and renal replacement therapy
Treatment Details
Interventions
- Vancomycin (Glycopeptide Antibiotic)
Vancomycin is already approved in United States, European Union, Canada, Japan for the following indications:
- Severe infections caused by susceptible strains of methicillin-resistant staphylococci
- Enterocolitis caused by Staphylococcus aureus
- Staphylococcal endocarditis
- Severe infections caused by Gram-positive bacteria
- Endocarditis
- Peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD)
- Severe infections caused by susceptible strains of methicillin-resistant staphylococci
- Enterocolitis caused by Staphylococcus aureus
- Severe infections caused by Gram-positive bacteria
- Endocarditis